NVG-111 is under clinical development by NovalGen and currently in Phase I for Non-Small Cell Lung Cancer. According to GlobalData, Phase I drugs for Non-Small Cell Lung Cancer have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how NVG-111’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

NVG-111 overview

NVG-111 is under development for treatment of relapsed and refractory chronic lymphocytic leukemia, small lymphocytic lymphoma and mantle cell lymphoma, solid tumor including non-small cell lung cancer, follicular lymphoma, diffuse large b-cell lymphoma, melanoma. It is administered through intravenous route. It is a Bi-specific T-cell engager (BiTE) antibody acts by targeting neurotrophic tyrosine kinase receptor related 1 (ROR1) and T-cells expressing CD3.

NovalGen overview

Novalgen is a biotechnology company. It develops molecular technologies and novel biological medicines for the treatment of cancer and other diseases. The company’s pipeline products include NVG-III-CLL for the treatment of chronic lymphocytic leukemia (CLL), NVG-III-MCL to treat mantle cell lymphoma, NVG-III-ALL indicated for acute leukemia and NVG-III-MM/RC treating malignant melanoma and renal carcinoma. It develops bi-specific T-cell engager (BiTEs) technology that targets receptor tyrosine kinase-like orphan receptor 1 (ROR1), a cell surface antigen present on a range of malignancies and cancer-initiating cells. The company serves in the therapeutic area of blood cancers, solid tumors, autoimmune diseases, hematology disorders, and infectious diseases. Novalgen is headquartered in Northwood Hills, Middlesex, the UK.

For a complete picture of NVG-111’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.